Mutual recognition agreements impact the import and export of pharmaceuticals by: Response:

Question

Options

• AEnsuring that product prices are consistent across borders.
• BRequiring additional testing for all imported or exported products.
• CFacilitating smoother regulatory approval processes between countries.
• DIncreasing the number of required inspections for each product.

• A
  3% (1)
• B
  6% (2)
• C
  76% (26)
• D
  15% (5)

Explanation

Mutual Recognition Agreements (MRAs) allow two or more countries to accept each other's regulatory decisions, certifications, and inspection findings - so when one country approves a pharmaceutical product or facility, partner countries recognize that approval rather than duplicating the entire review process, making C correct. Option A is wrong because MRAs address regulatory processes, not pricing, which is governed by separate trade or reimbursement policies. Option B is the opposite of what MRAs do - they reduce or eliminate redundant testing by trusting the originating country's data. Option D is similarly backwards; MRAs typically reduce inspection burdens by accepting inspections already performed by a trusted regulatory authority.

Memory tip: Think of MRAs as a "regulatory handshake" - countries agree to trust each other's homework, so no one has to redo it.

No community discussion yet for this question.